PEGylated rHDL Nanoparticles for Longer Brain-Targeted Circulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing reconstituted high-density lipoprotein nanoparticles (rHDL) face issues with rapid clearance from the bloodstream due to immune cell uptake, leading to low circulation capacity and inflammatory reactions, particularly when targeting the brain for neurodegenerative disease treatment.
Innovation Solution
Development of PEGylated reconstituted high-density lipoprotein nanoparticles (P-rHDL) using a specific synthetic mixing ratio of PEGylated lipid and apolipoprotein, which maintains stability and avoids immune cell phagocytosis while enhancing targeting efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If reconstituted high-density lipoprotein nanoparticles (rHDL) are injected into the body, then they can serve as therapeutic agents for neurodegenerative diseases, but they are rapidly cleared from the bloodstream by immune cells due to protein corona formation, leading to low circulation capacity and targeting efficiency
Solution Approach 1:
PEGylated lipids are introduced as an intermediary substance between the rHDL nanoparticle and the biological environment. The PEG chains form a protective hydrophilic shell around the nanoparticle, acting as a mediator that prevents direct interaction between the protein corona-forming surfaces and blood proteins, thereby reducing immune cell recognition and uptake while maintaining therapeutic function
Solution Approach 2:
The surface properties of the rHDL nanoparticle are modified by changing the chemical composition parameters - specifically incorporating PEGylated lipids at optimized molar ratios (0.5-10 mol%). This parameter change alters the surface hydrophilicity and steric properties, transforming the nanoparticle from an immunogenic state to a stealth state that evades immune clearance
2Ease of operation
If reconstituted high-density lipoprotein nanoparticles (rHDL) are injected into the body, then they can deliver therapeutic agents to target tissues, but they adsorb pro-inflammatory cytokines from blood proteins, causing secondary inflammatory reactions and side effects
Solution Approach 1:
The PEGylated lipid shell serves as a protective intermediary barrier between the rHDL nanoparticle core and pro-inflammatory cytokines in the blood. This mediator layer prevents the adsorption of harmful inflammatory proteins while allowing the nanoparticle to maintain its targeting capabilities through apolipoprotein E-mediated blood-brain barrier penetration
Solution Approach 2:
The PEGylation modification converts the potentially harmful immunogenic surface of the rHDL nanoparticle into a beneficial stealth surface. The same surface that would normally adsorb pro-inflammatory cytokines and trigger immune responses is transformed into a hydrophilic, non-fouling PEG shell that actively repels protein adsorption and provides anti-inflammatory properties
3Measurement precision
If antibody-based therapeutic agents are used to treat neurodegenerative diseases, then they can target pathological features effectively, but they cause cerebral edema or intracerebral microhemorrhages leading to fatal outcomes
Solution Approach 1:
Instead of using foreign antibody molecules that may cause adverse immune reactions, the invention uses reconstituted high-density lipoprotein nanoparticles that copy the structure and function of native HDL particles. These endogenous-like nanoparticles achieve targeting through apolipoprotein E recognition by LDL receptors on blood-brain barrier endothelial cells, providing a biocompatible alternative to antibody-based therapies
Solution Approach 2:
The therapeutic agent platform is changed from protein-based antibodies to lipid-based nanoparticles with specific compositional parameters (phospholipids, cholesterol, apolipoprotein E, and PEGylated lipids). This parameter change in the molecular nature of the therapeutic carrier eliminates the immunogenicity and adverse effects associated with antibodies while maintaining targeting precision through receptor-mediated transcytosis
Data Source
AI summary
PEGylated reconstituted high-density lipoprotein nanoparticles having the effect of preventing or treating neurodegenerative diseases are provided. Specifically, the present invention relates to nanoparticles and a method for producing the same, a phospholipid layer of the produced nanoparticles being protected by PEG due to PEG-lipid or a derivative thereof being included in the process of preparing a fluid comprising a hydrophobic material and a fluid comprising a hydrophilic material. The PEGylated nanoparticles have the ability to avoid the rejection mechanism of the immune response in the body while maintaining the existing transport ability across the blood-brain barrier, thereby having excellent stability and exhibiting long-term pharmacological effect due to high circulation ability in the body, and thus can be effectively utilized as a drug or a drug carrier.